Tumorvirus-specific Vaccination Strategies

Dr. Filipe Mariz, post-doc


© dkfz.de

Developing an L2-based prophylactic vaccine against HPV-related skin diseases

© dkfz.de

The infection of HPV in cutaneous sites is generally regarded as commensal, since the related hyperproliferative lesions (warts) are non-persistent and therefore regress overtime. In immunocompromised individuals, however, cutaneous HPV (cHPV) infection is commonly accompanied with severe and chronic illness. Particularly for organ transplant recipients, the majority of patients are suffering from cHPV-induced skin lesions during the course of chronic immune suppression and these lesions require costly and recurrent treatment. Additionally, increasing evidences support the role of cHPV infection in non-melanoma skin carcinogenesis.

Seeking a cost-efficient and broadly protective prophylactic vaccine against cHPV infection, we are currently assessing the effectiveness of HPV L2 polytopes fused to the bacterial Thioredoxin (Trx) scaffold protein as candidate vaccines in animal model. Of particular interest, the influence of a heptamerization domain (IMX313) in boosting both antibody and T-helper responses of the designed candidates is also under investigation.

  1. U. Wieland et al., Curr Probl Dermatol 45, 154-165 (2014).
  2. M. Tommasino, Virus Res 231, 128-138 (2017).
  3. H. Seitz et al., Cancer Prev Res 10, 932-41 (2015).

to top
powered by webEdition CMS